title: Inhibition of complex I by hydrophobic analogues of N-methyl-4-phenylpyridinium (MPP+) and the use of an ion-selective electrode to measure their accumulation by mitochondria and electron-transport particles.
abstract: N-methyl-4-phenylpyridinium (MPP+), the neurotoxic metabolite of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, kills dopaminergic neurons after its accumulation in mitochondria where it inhibits Complex I of the respiratory chain. MPP+ inhibits respiration by binding to both a hydrophobic and a hydrophilic site on Complex I and this inhibition is increased by the lipophilic tetraphenylboron anion (TPB-) which facilitates movement of MPP+ through membranes and its penetration to the hydrophobic binding site on Complex I. To investigate the inhibition of respiration by MPP(+)-like compounds, we have measured simultaneously NADH-linked mitochondrial respiration and the uptake and accumulation of the N-benzyl-4-styrylpyridinium and N-ethyl-4-styrylpyridinium cations in mitochondria using ion-selective electrodes. The data provide direct evidence that TPB- increases the inhibition not by increasing matrix concentration but by facilitating access to the inhibitory sites on Complex I. We have also compared the rates of uptake of MPP+ analogues of varied lipophilicity by the inner membrane and the development of inhibition of NADH oxidation, using an inverted mitochondrial inner membrane preparation and appropriate ion-selective electrodes. These experiments demonstrated that the amount of MPP+ analogue bound to the inner membrane greatly exceeded the quantity required for complete inhibition of NADH oxidation. Moreover, binding to the membrane occurred much more rapidly than the development of inhibition with all MPP+ analogues tested. This suggests that the attainment of a correct orientation of these compounds within the membrane and the binding site may be a rate-limiting step in the development of inhibition.
authors.affiliation: Department of Biochemistry, University of Otago, Dunedin, New Zealand.
authors.forename: M P
authors.initials: MP
authors.lastname: Murphy
authors.forename: M J
authors.initials: MJ
authors.lastname: Krueger
authors.forename: S O
authors.initials: SO
authors.lastname: Sablin
authors.forename: R R
authors.initials: RR
authors.lastname: Ramsay
authors.forename: T P
authors.initials: TP
authors.lastname: Singer
mesh_terms: D015655:1-Methyl-4-phenylpyridinium / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002412:Cations; D002417:Cattle; D004579:Electron Transport; D005260:Female; D007425:Intracellular Membranes / Q000378:metabolism; D017736:Ion-Selective Electrodes; D008929:Mitochondria, Heart; D008930:Mitochondria, Liver / Q000378:metabolism*; D009243:NAD / Q000378:metabolism; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000037:antagonists & inhibitors*; D010084:Oxidation-Reduction; D011726:Pyridinium Compounds / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002412:Cations; C092447:N-ethyl-4-styrylpyridinium; D011726:Pyridinium Compounds; D009243:NAD; C092448:N-benzyl-4-styrylpyridinium; D016660:NAD(P)H Dehydrogenase (Quinone); D015655:1-Methyl-4-phenylpyridinium